Penumbra (PEN) to Release Quarterly Earnings on Thursday

Penumbra (NYSE:PEN) is expected to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of $0.88 per share for the quarter. Penumbra has set its FY 2025 guidance at EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.

Penumbra (NYSE:PEN) last posted its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.09. The firm had revenue of $315.52 million for the quarter, compared to analysts’ expectations of $311.63 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. On average, analysts expect Penumbra to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Penumbra Trading Down 1.3 %

PEN opened at $287.81 on Tuesday. The stock has a market capitalization of $11.09 billion, a PE ratio of 846.49, a P/E/G ratio of 2.83 and a beta of 0.53. The firm’s fifty day moving average price is $259.90 and its 200 day moving average price is $229.52. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. Penumbra has a 12-month low of $148.00 and a 12-month high of $310.00.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on PEN. Royal Bank of Canada upped their price target on shares of Penumbra from $285.00 to $313.00 and gave the company an “outperform” rating in a report on Wednesday, February 19th. Oppenheimer initiated coverage on shares of Penumbra in a report on Tuesday, December 17th. They issued an “outperform” rating and a $275.00 price target on the stock. Morgan Stanley increased their target price on shares of Penumbra from $240.00 to $260.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 19th. Robert W. Baird increased their target price on shares of Penumbra from $305.00 to $328.00 and gave the stock an “outperform” rating in a report on Wednesday, February 19th. Finally, UBS Group increased their target price on shares of Penumbra from $305.00 to $320.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Penumbra has an average rating of “Moderate Buy” and a consensus price target of $292.64.

Insider Transactions at Penumbra

In other news, EVP Johanna Roberts sold 600 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $244.49, for a total transaction of $146,694.00. Following the completion of the transaction, the executive vice president now owns 63,444 shares in the company, valued at approximately $15,511,423.56. This represents a 0.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Harpreet Grewal sold 167 shares of the company’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $241.28, for a total transaction of $40,293.76. Following the transaction, the director now owns 8,530 shares of the company’s stock, valued at $2,058,118.40. This represents a 1.92 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 18,219 shares of company stock worth $4,426,439. Insiders own 5.00% of the company’s stock.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.